OC-0176: Urethral in vivo dosimetry in HDR prostate brachytherapy with Ir-192 and Co-60 sources  by Rodriguez Latorre, D.R.L. et al.
S86                                                                                                                                         3rd ESTRO Forum 2015 
 
dependence within the uncertainty of the measurements; 
hence no azimuthal and polar correction factors were applied 
to the measurements. No temperature dependence was 
found within the uncertainty of the measurement. The 
measured patient plans were in good agreement with the 
predicted voltage of the dosimeter with the minimum and 
maximum percentage differences between the measured and 
the predicted of -2.6% and -11.3% respectively. Further 
investigation of the causes of these differences and of per 
needle dose measurements to allow real-time error detection 
is still ongoing. Total uncertainty budget of this study was 
9.97% for k=2. An example of a clinical patient result is given 




Conclusions: Our study has demonstrated that 
implementation of real-time in-vivo dosimetry for HDR 
prostate brachytherapy using a MOSFET is feasible. Gross 
error detection is possible when the MOSFET is placed in a 
low dose gradient and appropriate correction factors are 
applied.  
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Purpose/Objective: To study if real time in vivo dosimetry, 
performed on the rectal surface with MOSkin detectors 
included on the trans rectal ultrasound (TRUS) probe, may 
evaluate possible discrepancies between calculated and 
delivered doses during US-based HDR prostate brachytherapy. 
Materials and Methods: MOSkins are a specific type of 
MOSFET dosimeter, optimized to measure dose in steep dose 
gradients. Their sensitive volume, defined by the volume of 
the gate oxide, is 4.8 x 10-6 mm3. In this study, two MOSkin 
dosimeters were calibrated and assembled on the surface of 
a TRUS-probe, used for real time on-line treatment planning 
in HDR prostate brachytherapy. During the treatment, the 
TRUS-probe was left inside the rectum and real time 
measures of the delivered dose were performed over 14 
treatment sessions (prescribed dose to the target surface: 
14Gy). 
Measured doses were compared to the doses calculated by 
means of the treatment planning system in the estimated 
detector position both on pre-treatment images (i.e., 
acquired 1-2 hours before treatment and used for treatment 
planning) and on post-treatment images (i.e., acquired 
within 3 minutes after treatment). In the latter case, the 
delivered dose distribution was retrospectively reconstructed 
and assumed as the reference. 
Results: Comparison between planned, reconstructed and in 
vivo measured doses, in terms of average absolute 




Data reported in the table shows that the highest accordance 
resulted between MOSkin readings and doses obtained on 
reconstructed plans, suggesting that in particular cases in 
vivo dosimetry might be a better instrument to estimate the 
dose to the rectum rather than the original treatment 
planning system itself. 
Comparing pre- and post-treatment images, it can be 
demonstrated that the high observed discrepancy between 
treatment and reconstructed plans is mainly due to 
anatomical variations of the prostate shape (i.e., prostate 
swelling with expanding inter-needles distances) and position 
(i.e., shift towards the rectal wall). This discrepancy 
correlated with the treatment planning time. 
Conclusions: Doses delivered to the organs at risk during HDR 
prostate brachytherapy might differ significantly from what is 
calculated in the treatment planning phase, providing the 
need for in vivo dosimetry in this particular radiotherapy 
application. MOSkin dosimeters integrated to the TRUS-probe 
proved to be an accurate instrument to perform real time 
measurement of the dose delivered to the rectal wall. The 
use of the dosimeters was incorporated in our department 
into clinical practice, actions protocol are still under study to 
potentially use the information acquired on-line. 
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Purpose/Objective: In vivo dosimetry (IVD) in brachytherapy 
(BT) is aimed to assess doses to organs at risk (OAR) by direct 
measurements. It is also an independent method to detect 
errors in dose delivery, and thus might be used as for patient 
QA of the whole BT process. Widely spread in external beam 
radiotherapy (EBRT), IVD in BT has faced some issues, mainly 
related to uncertainties due to high step gradients and 
detector positioning. 
In this study we present and analyze the results of in vivo 
dose determination in a urethral point with a group of HDR 
prostate patients (52 with Ir-192 and 10 with Co-60). Taking 
into account the uncertainties, the results and the system 
integration we evaluate the IVD system performance 
Materials and Methods: The electrometer (MultiDos, PTW) is 
integrated in the afterloader (MultiSource, Eckert & Ziegler 
BEBIG). The software to calibrate the dosimeter and to 
visualize the measured dose is integrated in the treatment 
console. 
The urethral probe (T9113, PTW) has a silicon diode in the tip 
of a rubber cable.To do the calibration we use a cylindrical 
phantom (Krieger phantom T9193, PTW). By means of a 
preconfigured plan in the MultiSource software the source is 
set in the Krieger phantom geometric center. Dose rate in 
the calibration point, set at 8 cm from the source position, is 
calculated through the source activity. The dose rate 
calculation takes into account the Krieger phantom's material 
(PMMA) and geometry which results in a factor 0.87 for Ir-
192, and 0.93 for Co-60 compared with water and full scatter 
conditions. Despite dose rate at 8 cm is very small, the 
calibration shows a good signal to noise ratio (>40). We 
observe a sensitivity loss of about 0.75% per month. 
Uncertainties involved in the calibration has been established 
in other studies, and are around 7% (k=1 type B). 
To do in vivo measurements, after needles insertion the 
detector is set in the urethra into a Foley catheter, and it is 
carried to an intermediate position, halfway between 
prostate base and apex, where dose gradients are expected 
to be smooth. A control point is set in the TPS (HDRplus 
3.0.6, E&Z BEBIG) representing the detector position using 
real time sagittal ultrasound images. 
Results: Measured dose deviation from that calculated with 
the TPS is in average -6.9%±4.0% (k=1 type A) for Ir-192 and -
4.6%±3.1% (k=1 type A) for Co-60. Due to fact that we are 
using real time images for assessing the position of both 
needles and detector, these results show a better agreement 
than other previously published (Waldhäusl, 2005; Sharma, 
2013). The negative systematic deviation might be caused by 
the effect of inter-needle attenuation, which is not taken 
into account in the TG-43 algorithm. 
Conclusions: Despite current 3D image-based dose 
calculation algorithms are more accurate than IVD for dose 
assessment of OARs, this integrated system provides a simple 
way to avoid mistakes in treatment administration. The 
uncertainties are considerably higher than those we are used 
to in EBRT, but still good enough to do a comprehensive 
patient QA. 
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Purpose/Objective: High dose rate (HDR) brachytherapy 
treatment is widely practiced but lacks independent routine 
treatment delivery verification to identify potential errors 
and ensure patient safety. We report our initial clinical 
experience with a novel, non-invasive, position-sensitive 
source-tracking system based on a flat panel detector (FPD) 
for treatment verification in HDR prostate brachytherapy. 
Materials and Methods: The FPD was mounted in a standard 
operating theatre couch (BetaStar, Marquet) under a 
customised carbon fibre couch top assembly. Four prostate 
patients (8 treatment fractions) were included in this initial 
study. At treatment each patient was aligned on the couch 
with the target region centred over the sensitive imaging 
area of the FPD. Prior to treatment, three x-ray dwell 
position markers were inserted into selected catheters and a 
radiograph captured with the FPD to localise the implant 
relative to the detector. As the HDR source treatment dwells 
were delivered, images were acquired with the FPD and post-
processed to determine the position of the source inside the 
patient. The source positions determined by the tracking 
system were compared to the treatment plan to verify 
correct treatment delivery. 
Results: Measured source dwell positions confirmed correct 
transfer tube connection, source step size and patient/plan 
selection. The mean linear distance between measured and 
planned positions (example fraction shown in Figure 1) was 
1.8mm (range 0.7 to 3.9mm) after rigid registration with the 
plan. The average measured dwell step size for all measured 
catheters was 2.5mm (range 1.9 to 3.1mm; s.d. 0.2mm). The 
absolute position of the measured source dwells was 
evaluated by comparing the measured dwell positions with x-
ray dwell position markers from the pre-treatment 
radiograph (mean 3.9mm, range 0.8 to 9.9mm). This, 
together with the implanted gold fiducial markers, visible on 
the radiograph, provided verification of programmed 
treatment indexer length and therefore delivery to the 
correct anatomical location. The total impact on procedure 
time was less than 15 minutes. 
Conclusions: The novel, non-invasive HDR brachytherapy 
treatment verification system was implemented clinically, 
providing verification of many treatment parameters by 
tracking the position of the HDR source as treatment was 
delivered. The novel application of the FPD allows 
verification that treatment delivery was free of most 
potential human related errors identified in ICRP 97. This 
concept and system will meaningfully improve safety 
standards by allowing routine treatment verification in HDR 
